Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Objective To assess over 3 years of follow-up the effects of maintaining or switching to
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …

Objective The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the
treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I …

Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …